NRIX Stock Analysis: Buy, Sell, or Hold?
NRIX - Nurix Therapeutics, Inc. Common stock
$18.65
1.10 (6.27%)
▲
5d:
+10.03%
30d:
+13.58%
90d:
+29.24%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 08, 2026
14d
Get Alerted When NRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NRIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NRIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NRIX is currently trading at $18.65, which is considered extended relative to its 30-day fair value range of $15.58 to $17.61.
Technical Outlook: Technically, NRIX is in a uptrend. The price is approaching resistance at $18.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: NRIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.44 (+68.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NRIX is in a uptrend. The price is approaching resistance at $18.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: NRIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.44 (+68.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.58 -
$17.61
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.3%)
- BULLISH: Trading 68.6% below Wall St target ($31.44)
Trading Range Analysis
30-Day Trading Range
$15.58 -
$17.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$14.67
Resistance Level
$18.91
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.98
Wall Street Target
$31.44
(+68.6%)
Revenue Growth (YoY)
-66.1%
Share & Embed Analysis
Last updated: June 23, 2026 6:04 AM ET
Data refreshes hourly during market hours. Next update: 7:04 AM
Data refreshes hourly during market hours. Next update: 7:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Gwenn Hansen
SELL
4895 shares
2026-01-30
Houte Hans Van
SELL
3661 shares
2026-01-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 60 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
